Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?
Abstract Background Pharmacological corticosteroid therapy is the standard of care in Duchenne Muscular Dystrophy (DMD) that aims to control symptoms and slow disease progression through potent anti-inflammatory action. However, a major concern is the significant adverse effects associated with long...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-03-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13023-021-01758-9 |
id |
doaj-f5cf0711b8b244ff9e7afbdbf56346c4 |
---|---|
record_format |
Article |
spelling |
doaj-f5cf0711b8b244ff9e7afbdbf56346c42021-03-11T11:27:22ZengBMCOrphanet Journal of Rare Diseases1750-11722021-03-011611910.1186/s13023-021-01758-9Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?Stephanie Kourakis0Cara A. Timpani1Dean G. Campelj2Patricia Hafner3Nuri Gueven4Dirk Fischer5Emma Rybalka6Institute for Health and Sport (IHeS), Victoria UniversityInstitute for Health and Sport (IHeS), Victoria UniversityInstitute for Health and Sport (IHeS), Victoria UniversityDivision of Neuropediatrics and Developmental Medicine, University Children’s Hospital of Basel (UKBB)School of Pharmacy and Pharmacology, University of TasmaniaDivision of Neuropediatrics and Developmental Medicine, University Children’s Hospital of Basel (UKBB)Institute for Health and Sport (IHeS), Victoria UniversityAbstract Background Pharmacological corticosteroid therapy is the standard of care in Duchenne Muscular Dystrophy (DMD) that aims to control symptoms and slow disease progression through potent anti-inflammatory action. However, a major concern is the significant adverse effects associated with long term-use. Main This review discusses the pros and cons of standard of care treatment for DMD and compares it to novel data generated with the new-wave dissociative corticosteroid, vamorolone. The current status of experimental anti-inflammatory pharmaceuticals is also reviewed, with insights regarding alternative drugs that could provide therapeutic advantage. Conclusions Although novel dissociative steroids may be superior substitutes to corticosteroids, other potential therapeutics should be explored. Repurposing or developing novel pharmacological therapies capable of addressing the many pathogenic features of DMD in addition to anti-inflammation could elicit greater therapeutic advantages.https://doi.org/10.1186/s13023-021-01758-9Duchenne muscular dystrophyCorticosteroidsStandard of careAnti-inflammatory drugsAnti-inflammation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Stephanie Kourakis Cara A. Timpani Dean G. Campelj Patricia Hafner Nuri Gueven Dirk Fischer Emma Rybalka |
spellingShingle |
Stephanie Kourakis Cara A. Timpani Dean G. Campelj Patricia Hafner Nuri Gueven Dirk Fischer Emma Rybalka Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better? Orphanet Journal of Rare Diseases Duchenne muscular dystrophy Corticosteroids Standard of care Anti-inflammatory drugs Anti-inflammation |
author_facet |
Stephanie Kourakis Cara A. Timpani Dean G. Campelj Patricia Hafner Nuri Gueven Dirk Fischer Emma Rybalka |
author_sort |
Stephanie Kourakis |
title |
Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better? |
title_short |
Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better? |
title_full |
Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better? |
title_fullStr |
Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better? |
title_full_unstemmed |
Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better? |
title_sort |
standard of care versus new-wave corticosteroids in the treatment of duchenne muscular dystrophy: can we do better? |
publisher |
BMC |
series |
Orphanet Journal of Rare Diseases |
issn |
1750-1172 |
publishDate |
2021-03-01 |
description |
Abstract Background Pharmacological corticosteroid therapy is the standard of care in Duchenne Muscular Dystrophy (DMD) that aims to control symptoms and slow disease progression through potent anti-inflammatory action. However, a major concern is the significant adverse effects associated with long term-use. Main This review discusses the pros and cons of standard of care treatment for DMD and compares it to novel data generated with the new-wave dissociative corticosteroid, vamorolone. The current status of experimental anti-inflammatory pharmaceuticals is also reviewed, with insights regarding alternative drugs that could provide therapeutic advantage. Conclusions Although novel dissociative steroids may be superior substitutes to corticosteroids, other potential therapeutics should be explored. Repurposing or developing novel pharmacological therapies capable of addressing the many pathogenic features of DMD in addition to anti-inflammation could elicit greater therapeutic advantages. |
topic |
Duchenne muscular dystrophy Corticosteroids Standard of care Anti-inflammatory drugs Anti-inflammation |
url |
https://doi.org/10.1186/s13023-021-01758-9 |
work_keys_str_mv |
AT stephaniekourakis standardofcareversusnewwavecorticosteroidsinthetreatmentofduchennemusculardystrophycanwedobetter AT caraatimpani standardofcareversusnewwavecorticosteroidsinthetreatmentofduchennemusculardystrophycanwedobetter AT deangcampelj standardofcareversusnewwavecorticosteroidsinthetreatmentofduchennemusculardystrophycanwedobetter AT patriciahafner standardofcareversusnewwavecorticosteroidsinthetreatmentofduchennemusculardystrophycanwedobetter AT nurigueven standardofcareversusnewwavecorticosteroidsinthetreatmentofduchennemusculardystrophycanwedobetter AT dirkfischer standardofcareversusnewwavecorticosteroidsinthetreatmentofduchennemusculardystrophycanwedobetter AT emmarybalka standardofcareversusnewwavecorticosteroidsinthetreatmentofduchennemusculardystrophycanwedobetter |
_version_ |
1724225662214995968 |